"Bruyère is a multi-site academic health care organization that is maximizing quality of life and helping people stay and return home. We deliver a wide variety of services in aging and rehabilitation, medically complex, palliative, residential and primary care. Our research leads to constant innovation in the services we provide with a focus on providing care that promotes independence. This work is enhanced by our Foundation that shares our story and raises funds with the support of our generous community."

During the past decade, Bruyere Continuing Care conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 6 clinical trials were completed, i.e. on average, 54.5% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 5 clinical trials were completed. i.e. 166.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Bruyere Continuing Care" #1 sponsor was "Bruyere Research Institute" with 4 trials, followed by "Anavex Life Sciences Corp." with 2 trials sponsored, "AstraZeneca" with 2 trials sponsored, "Biogen" with 2 trials sponsored and "Genentech, Inc." with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Bruyere Continuing Care" #1 collaborator was "Anavex Australia Pty Ltd." with 2 trials as a collaborator, "Anavex Germany GmbH" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Pfizer" with 2 trials as a collaborator and "University of Ottawa" with 2 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Bruyere Continuing Care" are "Alzheimer's Disease" (10 trials), "Alzheimer Disease" (3 trials), "Alzheimer´s Disease" (1 trials), "Brain Stimulation" (1 trials) and "Cancer" (1 trials). Many other conditions were trialed in "Bruyere Continuing Care" in a lesser frequency.

Most popular intervention types in "Bruyere Continuing Care" are "Drug" (13 trials), "Other" (4 trials), "Behavioral" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Crenezumab" (2 trials), "Lanabecestat" (2 trials), "placebo" (2 trials) and "'LIFEView'" (1 trials). Other intervention names were less common.

The vast majority of trials in "Bruyere Continuing Care" are 18 trials for "All" genders.

Currently, there are NaN active trials in "Bruyere Continuing Care". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Bruyere Continuing Care, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Bruyere Continuing Care, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".